XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Equity - USD ($)
$ in Thousands
Total
Impact of adoption
Common Stock
Additional Paid-In Capital
Additional Paid-In Capital
Impact of adoption
Treasury Stock
Accumulated Other Comprehensive Income
Retained Earnings
Retained Earnings
Impact of adoption
Beginning balance at Dec. 31, 2021 $ 12,888                
Increase (Decrease) in Temporary Equity [Roll Forward]                  
Accretion adjustments of redeemable noncontrolling interest to redemption value 2,569                
Net income / (loss) attributable to common stockholders (176)                
Ending balance at Mar. 31, 2022 15,281                
Beginning balance (in shares) at Dec. 31, 2021     50,407,000            
Beginning balance at Dec. 31, 2021 613,167 $ (46,543) $ 504 $ 498,979 $ (56,515) $ (5,149)   $ 118,833 $ 9,972
Beginning balance (in shares) at Dec. 31, 2021           147,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Common stock issued in connection with equity-based plans (in shares)     85,000            
Common stock issued in connection with equity-based plans 1,080   $ 1 1,079          
Purchases of treasury stock (in shares)           354,000      
Purchase of treasury stock (23,331)         $ (23,331)      
Stock-based compensation expense 12,110     12,110          
Accretion adjustments of redeemable noncontrolling interest to redemption value (2,569)     (2,569)          
Net income / (loss) attributable to common stockholders 9,079             9,079  
Other comprehensive income 0                
Ending balance (in shares) at Mar. 31, 2022     50,492,000            
Ending balance at Mar. 31, 2022 562,993   $ 505 453,084   $ (28,480)   137,884  
Ending balance (in shares) at Mar. 31, 2022           501,000      
Beginning balance at Dec. 31, 2022 23,988                
Increase (Decrease) in Temporary Equity [Roll Forward]                  
Accretion adjustments of redeemable noncontrolling interest to redemption value 2,061                
Net income / (loss) attributable to common stockholders (209)                
Ending balance at Mar. 31, 2023 $ 25,840                
Beginning balance (in shares) at Dec. 31, 2022 50,985,454   50,985,000            
Beginning balance at Dec. 31, 2022 $ 598,859   $ 510 497,199   $ (83,993) $ 0 185,143  
Beginning balance (in shares) at Dec. 31, 2022 1,532,745         1,533,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Common stock issued in connection with equity-based plans (in shares)     270,000            
Common stock issued in connection with equity-based plans $ 1,311   $ 3 1,308          
Stock-based compensation expense 12,686     12,686          
Accretion adjustments of redeemable noncontrolling interest to redemption value (2,061)     (2,061)          
Net income / (loss) attributable to common stockholders 14,416             14,416  
Other comprehensive income $ 170           170    
Ending balance (in shares) at Mar. 31, 2023 51,255,389   51,255,000            
Ending balance at Mar. 31, 2023 $ 625,381   $ 513 $ 509,132   $ (83,993) $ 170 $ 199,559  
Ending balance (in shares) at Mar. 31, 2023 1,532,745         1,533,000